1 / 12

Cheaper Kidney Care Vs.

Cheaper Kidney Care Vs. Redesigning kidney services to improve patient choice, shared decision making and deliver NHS costing savings. Impact of economic climate on pricing. PD patient numbers have fallen consistently during a period of increased economic pressures without price increases

lona
Download Presentation

Cheaper Kidney Care Vs.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cheaper Kidney Care Vs. Redesigning kidney services to improve patient choice, shared decision making and deliver NHS costing savings

  2. Impact of economic climate on pricing • PD patient numbers have fallen consistently during a period of increased economic pressures without price increases • Price decreases linked to initiatives to increase PD patient numbers have failed to drive growth in PD and have lead to regional price variations and differences in equity of access to advanced PD solutions • List prices for Baxter PD solutions have not increased to reflect increased cost of manufacture and distribution • Therapy prices include fluids, machines, Baxter and 3rd party ancillary products, technical and customer service support • The cost of APD to the NHS (staff, disposables and overheads) is still 35% less than in centre HD

  3. Baxter’s response to the National PD tender • Baxter’s response has been based on the tender specification and also the market evolution of Peritoneal Dialysis therapy in England over the past several years. • Over the past 5 years Baxter has endeavoured to hold or reduce prices whilst there has been a continual decline in the number of peritoneal dialysis patients. • Due to the high level of service support required to maintain patients at home we have been unable to leverage our costs and in real terms over the last 5 years we have experienced year on year increases in the costs of infrastructure and of the operation necessary to maintain a high level of patient and renal unit support. • Baxter’s response reflects what we believe is a fair cost of providing PD. • Redesigning kidney services to improve patient choice, shared decision making and deliver NHS costing savings – what is the role of PD as a clinical and cost effective therapy?

  4. Shared decision making: what does good look like? “Shared decision making is the key to good outcomes for people with advanced kidney disease. The work of NHS Kidney Care is making that a reality for more people and my goal is that 100 percent of people have choice”. 1 Open patient choice should be a key step as part of shared decision making. If a patient chooses home therapies, focus on how to make that work, rather than on obstacles. 2 At least 50% of patients starting on dialysis will be eligible for home treatment, 60% of patients eligible for home treatment will choose a home treatment if they are given appropriate education. 3 In the partnership or shared decision making approach, the practitioner genuinely does not disapprove of the decision the patient eventually chooses - it is the discussion that is important Dr O’Donoghue PRESS RELEASE 24 May 2010 NHS Kidney Care welcomes Secretary of State’s commitment to home dialysis Improving Choice for Kidney Patients: Five STEPS toolkit to Home Haemodialysis NHS Kidney Care February 2010 Renal Association Working Party on Peritoneal Dialysis Final Report 18.11.09

  5. The patient pathway Established Renal Failure (ERF) Conservative Care Renal Replacement Therapy (RRT) Benefits of PD as an initial modality? Initial survival advantage Preservation of vascular access Preservation of RRF If PD is no longer possible, a switch to Home Haemodialysis (HHD) would be a logical treatment option for patients preferring home- based care Home Transplant In - centre PD HHD

  6. Costs and reimbursement • The treatment of Established Renal Failure (ERF) is disproportionately costly using up to 2% of the NHS budget for less than 0.5% of the population1. • Non-mandatory tariff 2010/11 • Aim to move to a mandatory “best practice” tariff in 2011/12. • Best Practice Tariffs are specifically priced and structured in order to promote quality of care and value for money Erythropoiesis Stimulating Agents (ESAs) and Patient Transport Services (PTS)/Healthcare Travel Scheme (HTCS) costs excluded 1. National Service Framework for Renal Services: Part One – Dialysis and Transplantation. Department of Health. 2004 2. Baboolal K et al The cost of renal dialysis in a UK setting—a multi centre study Nephrol Dial Transplant (2008) 23: 1982–1989

  7. If just 30% of dialysis patients were treated at home it could save the NHS over £100 million Joseph, J and Laplante, S. NDT Plus (2010) 3 (suppl 3) iii91 (Sa182) Data projected forward to 2013 from 2008 Renal Registry Report

  8. Modelling the impact of dialysis modality mix on the cost to the Renal Unit of providing Renal Replacement Therapy (RRT) Using patient numbers and modality mix from Renal Units in London Increasing the number of dialysis patients treated at home from 15% in 2010 to 40% in 2014 could result in an annual cost saving of £12,459,644 in 2014 and cumulative cost savings of £31,370,101 over the 4 years Data on file using costs adapted from Baboolal K et al (2008) The cost of renal dialysis in a UK setting—a multicentre study Nephrol Dial Transplant 23: 1982–1989

  9. Impact of dialysis modality mix and reimbursement on Renal Unit contribution for provision of Renal Replacement Therapy Using patient numbers and modality mix from Renal Units in London If there are no changes in modality mix over the next 5 years the introduction of the Best Practice Tariff may lead to substantial losses in contribution. Increasing the number of dialysis patients treated at home to 40% by 2014 could lead to a continuation of positive contribution for the Renal Unit Contribution under current reimbursement Contribution under Best Practice Tariff Data on file using costs adapted from Baboolal K et al (2008) The cost of renal dialysis in a UK setting—a multicentre study Nephrol Dial Transplant 23: 1982–1989

  10. National PD tender Incentivising PD growth through Clinical KPI’s • Clinical KPI’s developed by the Clinical Procurement team to support the PD commissioning pathway • Sliding scale discount linked to quality • Reported via monthly commissioners report

  11. Commissioning for Quality and Innovation (CQUIN) targets: Incentivising home dialysis • Example of a recent business case • Unit has CQUIN to grow PD patient numbers by 10 by end of 2011 • The PD service is run by one full time PD nurse (Band 7), resulting in a nurse to patient ratio of 1:33 • Risk of forfeiting associated CQUIN payment as current PD staffing levels insufficient to support growth in the PD programme • The National Renal Workforce Planning Group (2002) recommended 1 whole time equivalent per 20 community dialysis patients with a skill mix of 5 nurses: 1 HCA • Increasing % dialysis patients treated with PD from 16% to 26% would save the trust £230,639 • Following presentation of business care the trust identified budget to recruitment of one additional nurse to enable the PD programme to expand

  12. Summary • PD patient numbers have fallen consistently during a period of increased economic pressures without price increases • Price decreases linked to initiatives to increase PD patient numbers have failed to drive growth in PD • PD offers a number of benefits as an initial modality? • Initial survival advantage • Preservation of vascular access • Preservation of RRF • If PD is no longer possible, a switch to Home Haemodialysis (HHD) would be a logical treatment option for patients preferring home- based care • Incentivising PD growth • Cost saving to the NHS • Commissioning for Quality and Innovation (CQUIN) targets • Clinical KPI’s linked to NPDT • Excel model and App available to model local impact of modality mix and reimbursement

More Related